Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Merck lowered its full-year profit guidance and said tariffs would mean an extra $200 million in costs this year. The stock ...

Several major drugmakers are counting on their manufacturing flexibility to counter potential disruptions from tariffs ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

Revenue for Q1 2025 reached $15.5 billion, driven by robust performances in oncology, animal health, and new product launches. The company reaffirmed its focus on research and development as a key ...

Julie Hyman provides an overview of the top stories of the trading day in just 60 seconds on Yahoo Finance's Market Minute. Merck & Company (MRK) warns investors that it expects a $200 million hit ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck (MRK) stock trades flat as Halozyme Therapeutics (HALO) files patent infringement suit linked to MRK's new injectable ...

Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid ...